Cost-effectiveness of pembrolizumab versus brentuximab vedotin for patients with relapsed or refractory classical Hodgkin’s lymphoma: a United States payer perspective

References

• American Cancer Society. Lymphoma. Atlanta, Georgia: ACS; 2015; Available at: http://www.cancer.org/cancer/hodgkindisease/detailedguide/hodgkin-disease-what-is-hodgkin-disease [Last accessed November 7, 2017]
   Google Scholar
• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN. Int J Cancer 2010;127:2893-917
   PubMed Web of Science ®Google Scholar
• Jemel A, Siegel R, Xu J, et al. Cancer statistics. CA Cancer 2010;60:277-300
   PubMed Web of Science ®Google Scholar
• Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med 2012;366:399-408
   PubMed Web of Science ®Google Scholar
• Merli F, Luminari S, Gobbi PG, et al. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol 2016;34:1175-81
   PubMed Web of Science ®Google Scholar
• Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009;27:4548-54
   PubMed Web of Science ®Google Scholar
• Nikolaenko L, Chen R, Herrera AF. Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma. Ther Adv Hematol 2017;8:293-302
   PubMed Web of Science ®Google Scholar
• Sweetenham JW, Carella AM, Taghipour G, et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin’s disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol 1999;17:3101-9
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Rowlings PA, Zhang MJ, et al. Autotransplants for Hodgkin’s disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 1999;17:534-45
   PubMed Web of Science ®Google Scholar
• Viviani S, Di Nicola M, Bonfante V, et al. Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience. Leuk Lymphoma 2010;51:1251-9
   PubMed Web of Science ®Google Scholar
• Gerrie AS, Power MM, Shepherd JD, et al. Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma. Ann Oncol 2014;25:2218-23
   PubMed Web of Science ®Google Scholar
• Lavoie JC, Connors JM, Philips GL, et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005;106:1473-8
   PubMed Web of Science ®Google Scholar
• Chopra R, McMillan AK, Linch DC, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin’s disease. A single-center eight-year study of 155 patients. Blood 1993;81:1137-45
   PubMed Web of Science ®Google Scholar
• Tarella C, Cuttica A, Vitolo U, et al. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. Cancer 2003;97:2748-59
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 2002;359:2065-71
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Perales MA, Kewalramani T, et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol 2009;146:158-63
   PubMed Web of Science ®Google Scholar
• Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol 2005;16:625-33
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Nimer SD, Zelenetz AD, et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin’s disease or aggressive non-Hodgkin’s lymphoma. Bone Marrow Transplant 2003;32:673-9
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Pembrolizumab (KEYTRUDA) for classical Hodgkin lymphoma. Washington, D.C.: US FDA; 2017. Available at: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm546893.htm [Last accessed November 24, 2017]
   Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. ADCETRIS: highlights of prescribing information. Washington, D.C.: US FDA; 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125388_S056S078lbl.pdf [Last accessed November 8, 2017]
   Google Scholar
• Cheah CY, Chihara D, Horowitz S, et al. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol 2016;27:1317-23
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics. Life Tables. Hyattsville, MD: NCHS; 2014. Available at: https://www.cdc.gov/nchs/products/life_tables.htm [Last accessed November 7, 2017]
   Google Scholar
• Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-8
   PubMed Web of Science ®Google Scholar
• Phillippo DM, Ades AE, Dias S, et al. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submission to NICE. Sheffield, UK: NICE; 2016. Available at: http://www.nicedsu.org.uk [Last accessed November 7, 2017]
   Google Scholar
• Merck, KEYNOTE-087 CSR. Kenilworth, NJ; Data on file; 2016
   Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30:2183-9
   PubMed Web of Science ®Google Scholar
• National Institute of Health and Care Excellence. Lymphoma (Hodgkin's, CD30-positive) - brentuximab vedotin [ID722]. London, UK: NICE; 2016. Available at: https://www.nice.org.uk/guidance/indevelopment/gid-tag467
   Google Scholar
• Merck, Kenilworth, NJ; Data on file. 2016
   Google Scholar
• Chen R, Gopal AK, Smith SE, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 2016;128:1562-6
   PubMed Web of Science ®Google Scholar
• Shao C, Liu J, Zhou W, et al. Utilization patterns and resource use in relapse/refractory Hodgkin lymphoma (rrHL) patients treated with brentuximab vedotin (BV). Blood 2016;128:2377
   Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108
   PubMed Web of Science ®Google Scholar
• Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005;43:203-20
   PubMed Web of Science ®Google Scholar
• Greiner W, Weijnen T, Nieuwenhuizen M, et al. A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ 2003;4:222-31
   PubMedGoogle Scholar
• Swinburn P, Shingler S, Acaster S, et al. Health utilities in relation to treatment response and adverse events in relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leuk Lymphoma 2015;56:1839-45
   PubMed Web of Science ®Google Scholar
• Szabo SM, Hirji I, Johnston KM, et al. Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: a retrospective cohort study. PLoS One 2017;12:e0180261
   PubMed Web of Science ®Google Scholar
• National Inpatient Sample 2017, Healthcare Cost and Utilization Project (HCUP). Kenilworth, NJ: Agency for Healthcare Research and Quality; 2017.
   Google Scholar
• Merck, US Market Research. Kenilworth, NJ; Data on file. 2017
   Google Scholar
• Rashidi A, Ebadi M, Cashen AF. Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis. Bone Marrow Transplant 2016;51:521-8
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007;18:1071-9
   PubMed Web of Science ®Google Scholar
• Shang EY, Solimando DA Jr, Waddell JA. Gemcitabine and vinorelbine (GemVin) regimen. Hosp Pharm 2014;49:508-16
   PubMedGoogle Scholar
• Moskowitz AJ, Hamlin PA Jr, Perales MA, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2013;31:456-60
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. GEMZAR (gemcitabine for injection): Highlights of prescribing information. Washington, D.C.: US FDA; 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020509s077lbl.pdf [Last accessed November 17, 2017]
   Google Scholar
• Nafees B, Stafford M, Gavriel S, et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 2008;6:84
   PubMed Web of Science ®Google Scholar
• Tolley K, Goad C, Yi Y, et al. Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia. Eur J Health Econ 2013;14:749-59
   PubMed Web of Science ®Google Scholar
• National Institute of Health and Care Excellence. Paclitaxel as albumin-boundnanoparticles with gemcitabine for untreated metastatic pancreatic cancer. London, UK: NICE; 2017. Available at: https://www.nice.org.uk/guidance/ta476/resources/paclitaxel-as-albuminbound-nanoparticles-with-gemcitabine-for-untreated-metastatic-pancreatic-cancer-pdf-82604969382085 [Last accessed November 7, 2017]
   Google Scholar
• National Institute of Health and Care Excellence. Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin’s B-cell lymphoma. London, UK: NICE; 2014. Available at: https://www.nice.org.uk/guidance/ta306/resources/pixantrone-monotherapy-for-treating-multiply-relapsed-or-refractory-aggressive-nonhodgkins-bcell-lymphoma-pdf-82602369336517 [Last accessed November 7, 2017]
   Google Scholar
• Best JH, Garrison LP, Hollingworth W, et al. Preference values associated with stage III colon cancer and adjuvant chemotherapy. Qual Life Res 2010;19:391-400
   PubMed Web of Science ®Google Scholar
• Beusterien KM, Davies J, Leach M, et al. Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study. Health Qual Life Outcomes 2010;8:50
   PubMed Web of Science ®Google Scholar